{"name":"Lynk Biotechnologies Pte Ltd","slug":"lynk-biotechnologies-pte-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Transdermal Glucosamine Cream","genericName":"Transdermal Glucosamine Cream","slug":"transdermal-glucosamine-cream","indication":"Osteoarthritis pain and joint support","status":"marketed"}]}],"pipeline":[{"name":"Transdermal Glucosamine Cream","genericName":"Transdermal Glucosamine Cream","slug":"transdermal-glucosamine-cream","phase":"marketed","mechanism":"Transdermal glucosamine cream delivers glucosamine through the skin to support cartilage structure and reduce joint inflammation.","indications":["Osteoarthritis pain and joint support"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-02","type":"trial","source":"The Manila Times","summary":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis - The Manila Times","headline":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZ0NOX1dOVnk1YnRoZGZNWjRaMmxFSEx3VzlzVWN4SUc1dkRLR19uSjU5ZWxwdjR3U3hEeW1fVGxwS3Fwb1ZtUVB0Nnp6WEZKNFU4ZTJaNDdFUDNvLXNuX2dGVEhtODVPU0hVVWRYTzhQbEFMUl8wVlhOUEZfb1VCaTAwa1BlQy11dlV1OVBVUkQtak9ldDBheXpCYw?oc=5","date":"2026-01-29","type":"deal","source":"The Pharma Letter","summary":"Formation Bio licenses miR-124 activator from China - The Pharma Letter","headline":"Formation Bio licenses miR-124 activator from China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQX1plRzhnRjVSdXpZeGZqUjhEa1pXNUlCRjc2VEIzS21aSVU3TkY2dFVtLVlCcU1GR0FyZml3a0YyV0lTMG16dC1aQXlvQUIwWEFKUUYzMURIcGxlWFhlc1NPZGNxRklYZDhkcDVBY0RKTFVtSndxMnZGcUR5N3ZjeXNGNFBfRHBoWDdvNFJEZGV1ZTBEMl9wNTdLOHU1SDZNc1FMbE5NYlc3YzdCRmpaVGpVRQ?oc=5","date":"2025-12-10","type":"deal","source":"The Pharma Letter","summary":"Formation Bio licenses CNS penetrant TYK2 inhibitor from Lynk Pharma - The Pharma Letter","headline":"Formation Bio licenses CNS penetrant TYK2 inhibitor from Lynk Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"prnewswire.com","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - prnewswire.com","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}